Original ArticlePemetrexed with or without Matuzumab as Second-Line Treatment for Patients with Stage IIIB/IV Non-small Cell Lung Cancer
Under an Elsevier user license
open archive
Key Words
Matuzumab
Pemetrexed
EGFR
NSCLC
Second-line
Humanized monoclonal antibody
Cited by (0)
Disclosure: Joan H. Schiller, MD, and Mark A. Socinski, MD, declared that their institutions received research funding from Merck KGaA to support this clinical trial. Robert Pirker, MD, and Martin Sebastian, MD, reported receiving advisory board honoraria from Merck Serono. Claire Beadman, BSc (Hons), PG Dip, Pharm Med, is a current employee of the study sponsor. All other authors declared no conflicts of interest.
Copyright © 2010 International Association for the Study of Lung Cancer. All rights reserved.